Printer Friendly

VESTAR'S AMBISOME GAINS FULL MARKETING APPROVAL IN THE NETHERLANDS

 SAN DIMAS, Calif., June 7 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) today announced that AmBisome(R), the company's liposomal formulation of amphotericin B, has received full marketing approval from the College Ter Beoordeling Van Geneesmiddelen in The Netherlands, as a treatment for systemic fungal infections. The Netherlands is the seventh country to grant full marketing approval for AmBisome. The commercial launch of the product is expected to begin immediately.
 "This action in The Netherlands represents the first approval to be granted from the company's second round of regulatory filings for AmBisome," said Roger J. Crossley, M.D., chairman, CEO and president of Vestar. "This important approval will further strengthen the European market position of AmBisome, which has already received tremendous medical acceptance as the treatment of choice for systemic fungal infections."
 Vestar management noted that AmBisome received full marketing approval in six countries during late 1991 and 1992: Ireland, Mexico, the United Kingdom, Sweden, Germany and Portugal. The Netherlands is the first country to approve the drug during 1993.
 AmBisome is Vestar's trade name for its proprietary intravenous liposomal formulation of amphotericin B, the most commonly used drug for severe systemic fungal infections. The use of conventional amphotericin B has been severely limited by its serious toxicity at doses that are only marginally effective. In contrast, clinical data have demonstrated that AmBisome is well tolerated, permitting higher daily and cumulative doses then are considered safe for the conventional drug.
 Systemic fungal infections are serious infections with a mortality rate of up to 70 percent, that often occur in cancer patients treated with chemotherapy, particularly those with leukemia, as well as organ and bone marrow transplant patients, and AIDS patients. In clinical trials of AmBisome to date, 85 percent of patients have shown clinical improvement against a variety of fungal infections, with minimal side effects. With this positive safety and efficacy profile for AmBisome, Phase III and IV trials are underway with a view toward gaining approval for use of the drug in the treatment process.
 Vestar, headquartered in San Dimas, Calif., develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. Since 1989, Vestar has been marketing in Europe AmBisome, a liposomal formulation of amphotericin B, to treat systemic fungal infections. DaunoXome(R), a liposomal formulation of the chemotherapeutic agent daunorubicin, is Vestar's second major product. MiKasome, a liposomal formulation of the antibiotic amikacin, is currently in preclinical trials for potential use against drug- resistant tuberculosis. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, and lipid prodrug technology for the development of orally active compounds.
 -0- 6/7/93
 /CONTACT: Michael E. Hart, chief financial officer, Vestar, Inc., 909-394-4119; Marcia A. Kean, executive VP, Feinstein Partners Inc., 617-577-8110, for Vestar/
 (VSTR)


CO: Vestar, Inc. ST: California IN: MTC SU:

DJ -- NE005 -- 5826 06/07/93 08:46 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 7, 1993
Words:476
Previous Article:NEW CRITERIA GIVE NETWORK WORLD MOST HIGHLY QUALIFIED SUBSCRIBERS
Next Article:MULTIBANK CONTINUES TO CONSIDER ACQUISITION BY BANK OF BOSTON
Topics:


Related Articles
VESTAR'S AMBISOME(R) GAINS MARKETING APPROVAL IN THE UNITED KINGDOM
VESTAR'S AMBISOME GAINS MARKETING AND REIMBURSEMENT APPROVAL IN SWEDEN
VESTAR TO EXPAND PRODUCTION FACILITIES; SIGNS LEASE FOR 51,000-SQUARE-FOOT FACILITY
VESTAR TO EXPAND PRODUCTION FACILITIES; SIGNS LEASE FOR 51,000-SQUARE-FOOT FACILITY
VESTAR'S AMBISOME(R) GAINS MARKETING APPROVAL IN GERMANY
VESTAR'S AMBISOME GAINS FULL MARKETING APPROVAL IN PORTUGAL
FUJISAWA USA FILES IND APPLICATION FOR VESTAR'S AMBISOME(R)
VESTAR'S AMBISOME GAINS FULL MARKETING APPROVAL IN GREECE
VESTAR REPORTS SECOND QUARTER 1993 RESULTS; REVENUES UP 34 PERCENT AS R&D AND MARKETING EXPENDITURES ACCELERATE
VESTAR GRANTED REGULATORY APPROVAL IN SWEDEN FOR AMBISOME(R) PRODUCT ENHANCEMENTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters